



1/2022 (volume 4, Issue 1)

http://ijma.journals.ekb.eg/

Print ISSN: 2636-4174 Online ISSN: 2682-3780


About IJMA

- International Journal of Medical Arts is the Official Scientific Journal of the Damietta Faculty of Medicine, Al-Azhar University, Egypt
- It is an International, Open Access, Double-blind, Peer-reviewed, monthly-published (starting January 2022) Journal
- The First Issue was published in July 2019
- Published under the following license: Creative Commons Attribution-ShareAlike 4.0 International Public License (CC BY-SA 4.0).
- The Egyptian Knowledge Bank hosts the web site and supports IJMA
- IJMA follows the regulations of the International Committee of Medical Journal Editors
- IJMA is a member of the International Society of Managing and
- Technical Editors
- IJMA is indexed in the "Directory of Open Access Journals" [Indexed on 15 January 2021], Index Copernicus and J-Gate [29-6-2021].
- IJMA Listed in

"Publons", "Academic resource index [ResearchBib]", "Electronics journal library", "Eurasian Scientific Journal Index", World Catalogue of Scientific Journals, Information Matrix for the Analysis of Journals (MIAR) live 2021, WorldCat and "Citefactor"

• IJMA introduced to the search engine [BASE] through DOAJ





Original Article


Available online at Journal Website https://ijma.journals.ekb.eg/ Main Subject [Surgery] Specific Subject [Urology]



Monopolar versus Bipolar Transurethral Resection of Non-Muscle Invasive Bladder Cancer

Rabee Abdallah Yassein *^[1], Ayman Mohtady Edrees ^[1], Mohamed Abdelhameed Khalil ^[1]

¹ Department of Urology, Faculty of Medicine [for girls], Al-Azhar University, Cairo, Egypt



Keywords: Monopolar; Bipolar transurethral resection; Non-muscle invasive bladder cancer

This is an open-access article registered under the Creative Commons, ShareAlike 4.0 International license [CC BY-SA 4.0] [https://creativecommons.org/licenses/by-sa/4.0/legalcode.

INTRODUCTION

Bladder cancer is the second commonest malignancy of the urinary system after prostate cancer ^[1]. Nearly, 75-80% of urothelial cancer present as [NMIBC], while 20-25% present as muscle invasive tumor ^[2]. TURBT is the essential step for the management of [NMIBC], in order to reach actual diagnosis and clear all tumors in the bladder involved part of the underlying muscle ^[3].

Many resectoscopes are divided roughly into monopolar and bipolar instruments. The bipolar technique is one of the most recent advancements in Urology ^[3]. Configuration of the current pathway is considered the essential difference between monopolar and bipolar instruments. The Bipolar one is able to act in a conductive fluid medium [normal saline] in contrast to the conventional non-conductive irrigation fluid [glycine, sorbitol and mannitol]. Recently, the plasma-kinetic resectoscope has been incorporated, mainly for transurethral resection of the prostate [4, 5].

In bipolar resectoscope, power is passed from the loop electrode into the normal saline, promoting it to evaporate and form an interface layer of gas around the loop. The addition of voltage to the gas causes excitation of the sodium ions to form plasma, a highly energized state of matter^[6].

THE AIM OF THE WORK

Although many clinical trials were conducted to compare the between both techniques [mono-polar vs. bipolar], no consensus guidelines are available until now; in addition, few studies were from developing countries. Therefore, this study aims to comparison between plasmakinetic bipolar resectoscope and traditionally monopolar in the transurethral resection of primary NMIBT as regard safety & efficacy.

PATIENTS AND METHODS

This study is a prospective randomized study that included 80 patients [70 males and 10 females] aged 36 years or older with urinary bladder mass. They were selected from Urology out-patient clinic at Al-Zahraa University Hospital, from March 2016 to March 2020. Patients presented with de novo primary vesicle tumor were included in the study, whilst, invasive bladder cancer, recurrent cases, urethral stricture, active urinary tract infection [UTI] and uncontrolled hypertension or bleeding diathesis were excluded from this study.

Preoperative assessment

Patients were randomly classified into two groups. Group [A] included 40 patients underwent M-TURBT and Group [B] included 40 patients underwent B-TURBT. All cases were evaluated before operation by full history taking, physical examination, laboratory investigations: Urine analysis and culture & sensitivity if indicated, CBC, coagulation profile, fasting and post-prandial blood sugar, renal & liver function tests, and serum sodium & potassium level. Radiological evaluation included renal ultra-sonography, contrasted CT scan, and chest x-ray. Patients with infected urine were treated with antibiotics after culture and sensitivity. Pre-operatively, patients must discontinue anti-coagulants and antiplatelet drugs 5-7 days. Patients on warfarin should be replacing by low molecular weight heparin. All achieve patients will an international normalized ratio [INR] of < 1.5 within 4-5 days of stopping warfarin. Intravenous broad spectrum antibiotics were given one hour before the procedure.

Procedures

The patient placed in dorsal lithotomy position after induction of general or spinal anesthesia. Digital rectal exam [DRE] under anesthesia was done before starting the procedures. The technique initiated by pan urethrocystoscopy, evaluating the urinary bladder mass & its size, shape, and location, and determining any other abnormalities.

The traditional monopolar technique was performed through a Storz 26-F resectoscope with continuous flow, 1.5% glycine was used as the irrigant. The generator was programmed to70W for both cutting and coagulation. While in bipolar technique, it was carried out by the Storz transurethral resection in saline with a continuous-flow 26-F resectoscope, and 0.9% normal saline was used as the irrigant. The generator was adjusted to 70 W for cutting and 80 W for coagulation from ERBE VIO 300 D, generator machine.

In both groups, after total resection of all vesical masses, good homeostasis was done and a 22-F triple-way catheter was fixed. DRE was done again at the end of the procedure. Any Intraoperative complications as, obturator jerk, perforation, and TUR syndrome were noted. If initial resection isn't complete as the specimen not includes muscle or T1 stage, transurethral resection should be repeated 2 to 6 weeks from the initial resection for adequate staging of the tumor.

The removed tumors were referred to Pathology unit, fixed in saline and formalin, to examined specimen for cancer stage and grading. Irrigation of bladder was done till

Yassein et al.

urine became clear, the urethral catheter removed and patient discharge when became stable. Measurement of hemoglobin [Hb], hematocrit level, serum sodium [Na] and potassium were completed within 24 hours postoperatively. Age of patients, sex, tumors size, site, shape and number, time of resection from the start of resection till the removal of resectoscope sheath], the intra and postoperative complications, changes in Hb, and Na, time of catheterization, hospital stay, pathological stage, WHO grade, and rate of recurrence all were recorded. Postoperative intravesical immunotherapy was given to all cases every week for six weeks started one month after resection.

Follow-up: The patients were followed after 3, 6, 9 and 12 months from the first resection by pelvi-abdominal ultrasonography, urine cytology, and cystoscopy.

Data Collection and Analysis

Recorded data were analyzed using the statistical package for social sciences, version 20.0. [SPSS Inc., Chicago, IL, USA]. Quantitative data were presented as means standard deviation [SD]. Qualitative data were evaluated as frequency and percentage. The following tests were performed: Independent-samples t-test of significance was used when comparing between two means, chi-square [x2] test of significance was used in order to compare proportions between qualitative parameters, the confidence interval was set to 5%. So, the p-value was considered

significant as the following: <0.05 as significant, and P-value >0.05 as insignificant.

Ethical considerations

A written consent was signed by all cases that included in this research and they informed about the procedure and the rate of its success and potential complications. Approval of the International Review Board [IRB] was obtained.

RESULTS

There were no statistically significant difference regarding demographic data and tumor characteristic between the studied groups [Table 1 & 2].

There were mild drop in HB level and hematocrit value in Group A, but without significant difference, and no patient required blood transfusion [Table3].

The hospital stay and catheterization time were significantly reduced in B-polar [TURBT] than M-polar [TURBT] [Table 4].

There was no statistically significant difference in two studied groups regarding intraoperative & postoperative complications except for obturator jerk that was higher in Mpolar group than B-polar group [Table 5].

There was no significant difference between either groups as regard to recurrence rater after one year follow-up with US & cystoscopy every 3 months [Table 6].

		M-POLAR TURBT [n=40]	B-POLAR TURBT [n=40]	Test	p-value
Sex	Males	33 [82.5%]	36 [90%]	<i>x</i> ₂ =0.949	0.330
	Females	7 [17.5%]	4 [10%]		
Age [years]	Mean+SD	57.90+9.05	60.13+7.29	t=1.467	0.23
	Range	38-75	45-75		
Tumor characters	Single	29 [72.5%]	32 [80%]	<i>x</i> ₂ =1.370	0.504
	Multiple	11 [27.5%]	8 [20%]		
Tumor size [cm] ²	Mean±SD	1.87±0.56	2.06 ± 0.58	t=1.490	0.140
	Range	1-2.5	1-3		
Time of operation	Mean±SD	35.38±7.63	33.63±7.76	<i>t</i> =1.017	0.312
[min]	Range	20-50	25-45		

Table [1]: Demographic data and tumour character

Table [2]: Comparison between M-polar TURBT and B-polar TURBT according to their location

location									
	M-POLAR TURBT [n=40]			B-POLAR TURBT [n=40]			P1	P2	P3
	No.	Size	Time	No.	Size	Time			
Rt. Lateral wall	10 [25%]	1 -2.5	25-50	15 [37.5%]	1 -2	30-45	0.231	> 0.05	> 0.05
Lt. Lateral wall	12 [30.0%]	1 -2	20-40	15 [37.5%]	1 -	25-50	0.481	> 0.05	> 0.05
					2.5				
Ant. Wall	4 [10.0%]	1 -1.5	25-35	2 [5.0%]	1 -2	20-40	0.399	> 0.05	> 0.05
Trigonal	3 [7.5%]	1.5-2	20-30	1 [2.5%]	1.5	25	0.308	> 0.05	> 0.05
Domal	1 [2.5%]	1	30	1 [2.5%]	1.2	35	1.000	> 0.05	> 0.05
Basal	10 [25%]	1 -2.5	20-50	6 [15.0%]	1 -3	25-45	0.267	> 0.05	> 0.05
Involvement of	1 [2.5%]	1.5.	30	2 [5.0%]	1	25	0.559	> 0.05	> 0.05
ureteric orifices									

P1: Comparison between two groups according location, P2: Comparison between two groups according size, P3: Comparison between two groups according time.

level								
		M-POLAR TURBT [n=40]	B-POLAR TURBT [n=40]	t-test	p-value			
Hemoglobin [gm/dl]								
Preoperative	Mean±SD Range	13.37±1.24 10.5-14	13.65±1.06 11.4-15.2	1.086	0.281			
Postoperative	Mean±SD Range	12.81±1.17 10.0-13.2	13.15±1.11 11-14.8	1.333	0.186			
Reduction	Mean±SD Range	0.56±0.72 0.5-1.7	0.50±0.44 0.1-1.5	0.450	0.654			
Hematocrit [gm%]							
Preoperative	Mean±SD Range	44.37±5.32 39-48	44.31±6.13 40-47	0.047	0.963			
Postoperative	Mean±SD Range	39.76±4.65 33-43	40.80±4.90 35-45	0.974	0.333			
Reduction	Mean±SD Range	4.61±4.48 2-8	3.57±3.21 1-7	1.193	0.236			
Sodium [MEQ/L]								
Preoperative	Mean±SD Range	142.00±2.08 136-145	142.20±1.98 135-147	0.195	0.661			
Postoperative	Mean±SD Range	140.78±2.51 133-142	140.74±2.37 134-144	0.055	0.956			
Reduction	Mean±SD Range	1.22±0.69 0.5-1.8	1.42±0.51 0.2-1.3	1.555	0.124			

Table [3]: Comparison between pre & post-operative hemoglobin, haematocrit and sodium

 Table [4]: Comparison between two groups according to their post-operative time of catheterization and hospital stay

		M-POLAR TURBT [n=40]	B-POLAR TURBT [n=40]	t-test	p-value
Time of cathetralization [day]	Mean±SD Range	3.13±0.70 3-4	2.73±0.42 2-3	3.099	0.003*
Time of hospitalization [day]	Mean±SD Range	4.53±1.70 3-5	3.57±1.42 3-5	2.741	0.008*

Table [5]: Comparison between two groups according to intra and post-operative

complications								
	TURBT M-	TURBT B-	x2	p-value				
	POLAR [n=40]	POLAR [n=40]						
Intraoperative complications								
Obturator jerk	10 [25.0%]	2 [5.0%]	6.916	0.013*				
Bladder perforation	0 [0.0%]	0 [0.0%]						
TUR syndrome	0 [0.0%]	0 [0.0%]						
Postoperative complications								
Hematuria	7 [17.5%]	6 [15.0%]	0.091	0.763				
Clot retention	0 [0.0%]	0 [0.0%]						
Blood transfusion	3 [7.5%]	1 [2.5%]	1.039	0.308				

x²: Chi-square test; p-value>0.05 NS; *p-value <0.05 S.

Table [6]: Number, site, grade and stage of recurrence in both groups at 3, 6, 9 and 12 months[By US and cystoscopy]

Site Another site recurrence Same site of primary tumor 4 [100%] 0 [0%] 1 [33.3%] 2 [66.7%] 3.202 0.074 Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0 [0%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 2 [66.7%] 2 [50.0%] 2 [50.0%] 0.167 0.683 Grade Same grade Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.00 1.00 Grade Same grade Same stage Progression 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 4 [100%] 0 [0%] 0.00 1.00 Grade Same site of primary tumor 3 [100%] 3 [100%] 0 [0%] 0.00 1.00 Grade Another site recurrence<		-				
Recurrence at 3 months 4 [10.0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 4 [100%] 1 [33.3%] 3.202 0.074 Grade Same grade 4 [100%] 0 [0%] 2 [66.7%] 0.00 1.00 Stage Same stage 4 [100%] 0 [0%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [100%] 0.155 0.694 Site Another site recurrence 1 [33.3%] 2 [50.0%] 0.167 0.683 Grade Same grade 3 [100%] 4 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0.00 1.00 1.00 Brace Another site recurrence 1 [25.0%] 0 [0%] 0.750			M-POLAR	B-POLAR	x2	р-
Site Another site recurrence Same site of primary tumor 4 [100%] 0 [0%] 1 [33.3%] 2 [66.7%] 3.202 0.074 Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [100%] 2 [50.0%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.167 0.683 Grade Same grade Progression 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Stage Same stage Same stage 4 [10.0%] 0 [0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence Same stage 4 [10.0%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Grade Same stage 4 [100%] 0 [0%]			TURBT [n=40]	TURBT [n=40]		value
Same site of primary tumor 0 [0%] 2 [66.7%] Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0 [0%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.167 0.883 Grade Same grade Progression 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Grade Same stage Same stage 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Grade Same grade 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Grade Same grade 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 0 [0	Recurrence at 3 months		4 [10.0%]	3 [7.5%]	0.155	0.694
Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0 [0%] 0.00 1.00 Site Another site recurrence Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.167 0.683 Grade Same grade Progression 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Bite Another site recurrence 1 [25.0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0 [0%] 0.00 1.00 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Bite Another site recurrence 1 [25.0%] 0 [0%] 0.00 1.00 Progression<	Site	Another site recurrence	4 [100%]	1 [33.3%]	3.202	0.074
Progression 0 [0%] 0 [0%] 0 [0%] Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0 [0%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 2 [66.7%] 2 [50.0%] 2 [50.0%] 0 [0%] 0.00 1.00 Grade Same grade Progression 3 [100%] 4 [100%] 0 [0%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Grade Same stage 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0.00 1.00 Brage Same stage 4 [100%] 3 [100%] 0.00 1.00<		Same site of primary tumor	0 [0%]	2 [66.7%]		
Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.167 0.683 Grade Same grade Progression 3 [100%] 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage Progression 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Progression 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0.00 1.00 Grade Same stage 4 [100%] 3 [100%] 0.00 1.00 Sit	Grade	Same grade	4 [100%]	3 [100%]	0.00	1.00
Progression 0 [0%] 0 [0%] 0 [0%] 0 [0%] Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0.155 0.694 Site Another site recurrence 1 [33.3%] 2 [50.0%] 0.167 0.683 Site Another site of primary tumor 2 [66.7%] 2 [50.0%] 0.167 0.683 Grade Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.00 1.00 Grade Same grade 3 [100%] 4 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0 0.00 1.00 Stage Same stage 3 [100%] 4 [100%] 0 [0%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0.750 0.387 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00		Progression	0 [0%]	0 [0%]		
Progression 0 [0%] 0 [0%] 0 [0%] Recurrence at 6 months 3 [7.5%] 4 [10.0%] 0.155 0.694 Site Another site recurrence 1 [33.3%] 2 [50.0%] 0.167 0.683 Same site of primary tumor 2 [66.7%] 2 [50.0%] 0.167 0.683 Grade Same grade 3 [100%] 4 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 3 [100%] 4 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0 [0%] 0.00 1.00 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Site Another site recurrence 1 [0%] 3 [100%] 0 [0%] 0.00 1.00	Stage	Same stage	4 [100%]	3 [100%]	0.00	1.00
Site Another site recurrence Same site of primary tumor 1 [33.3%] 2 [50.0%] 0.167 0.683 Grade Same grade Progression 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Progression 3 [100%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage Progression 3 [100%] 4 [100%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0 [0%] 0.750 0.387 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Grade Same stage 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage 2 [66.7%]	0	Progression	0 [0%]	0 [0%]		
Same site of primary tumor 2 [66.7%] 2 [50.0%] Grade Same grade Progression 3 [100%] 4 [100%] 0.00 1.00 Stage Same stage Progression 3 [100%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage Progression 3 [100%] 4 [100%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 0 [0%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0.750 0.387 Grade Same site of primary tumor 3 [100%] 3 [100%] 0.00 1.00 Grade Same stage grade 4 [100%] 3 [100%] 0.00 1.00 Grade Same stage grade 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Brogression 0 [0%] 0 [0%] 0.00 1.00 Brogression 0 [0%] 0 [0%] 0.00 1.00 Same site of primary tumor <th< th=""><td>Recurrence</td><td>at 6 months</td><td>3 [7.5%]</td><td>4 [10.0%]</td><td>0.155</td><td>0.694</td></th<>	Recurrence	at 6 months	3 [7.5%]	4 [10.0%]	0.155	0.694
Grade Same grade Progression 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 0 [0%] 0 [0%] 0 [0%] 0 [0%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 1 [25.0%] 0 [0%] 0.155 0.694 Grade Same grade Progression 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage grade Progression 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Brogression 0 [0%] 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage Progression 2 [66.7%] 3 [7.5%] 0.00 1.00 Site Another site recurrence Same site of primary tumor 1 [33.3%] 2 [66.7%] 0 [0%] 0.558 0.455 Grade Same grade Progression 2 [66.7%]	Site	Another site recurrence	1 [33.3%]	2 [50.0%]	0.167	0.683
Progression 0 [0%] 0 [0%] 0 [0%] 0 [0%] Stage Same stage Progression 3 [100%] 4 [100%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Site Another site recurrence 1 [25.0%] 0 [0%] 0.750 0.387 Site Another site recurrence 1 [25.0%] 0 [0%] 0.00 1.00 Grade Same site of primary tumor 3 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage 2 [66.7%] 3 [7.5%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 3 [100%] 0.558 </th <td></td> <td>Same site of primary tumor</td> <td>2 [66.7%]</td> <td>2 [50.0%]</td> <td></td> <td></td>		Same site of primary tumor	2 [66.7%]	2 [50.0%]		
Stage Same stage Progression 3 [100%] 0 [0%] 4 [100%] 0 [0%] 0.00 1.00 Recurrence at 9 months 4 [10.0%] Another site recurrence 4 [10.0%] 1 [25.0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence Same site of primary tumor 1 [25.0%] 3 [100%] 0 [0%] 0.750 0.387 Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Site Another site recurrence Same site of primary tumor 3 [7.5%] 3 [7.5%] 0.00 1.00 Stage Same grade Progression 2 [66.7%] 1 [33.3%] 0.558 0.455 Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Brogression 1 [33.3%] 0 [0%] 2 [66.7%]<	Grade	Same grade	3 [100%]	4 [100%]	0.00	1.00
Progression 0 [0%] 0 [0%] 0 [0%] Recurrence at 9 months 4 [10.0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0 [0%] 0.750 0.387 Same site of primary tumor 3 [100%] 3 [100%] 0.00 1.00 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 1 [33.3%] 0.558 0.455 Same site of primary tumor 1 [33.3%] 2 [66.7%] 3 [100%] 0.999 0.318 Brogression <th< th=""><td></td><td>Progression</td><td>0 [0%]</td><td>0 [0%]</td><td></td><td></td></th<>		Progression	0 [0%]	0 [0%]		
Recurrence at 9 months 4 [10.0%] 3 [7.5%] 0.155 0.694 Site Another site recurrence 1 [25.0%] 0 [0%] 0.750 0.387 Same site of primary tumor 3 [100%] 3 [100%] 3 [100%] 0.00 1.00 Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 1 [33.3%] 0.558 0.455 Same site of primary tumor 1 [33.3%] 2 [66.7%] 3 [100%] 0.999 0.318 Progression 1 [33.3%] 0 [0%] 0 [0%] 0 [0%] 0 [0%] S	Stage	e	3 [100%]	4 [100%]	0.00	1.00
Site Another site recurrence Same site of primary tumor 1 [25.0%] 3 [100%] 0 [0%] 3 [100%] 0.750 0.387 Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Stage Same stage Same stage 4 [100%] 0 [0%] 3 [100%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence Same site of primary tumor 1 [33.3%] 2 [66.7%] 1 [33.3%] 0.558 0.455 Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Brogression 1 [33.3%] 0 [0%] 3 [100%] 2.502 0.114		Progression	0 [0%]	0 [0%]		
Same site of primary tumor 3 [100%] 3 [100%] 3 [100%] Grade Same grade 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 0 [0%] 0 [0%] 0.00 1.00 Stage Same stage 4 [100%] 0 [0%] 0 [0%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 0 [0%] 0 [0%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 1 [33.3%] 0.558 0.455 Same site of primary tumor 1 [33.3%] 2 [66.7%] 3 [100%] 0.999 0.318 Grade Same grade 2 [66.7%] 3 [100%] 0.999 0.318 Progression 1 [33.3%] 0 [0%] 0 [0%] 0 [0%] Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114	Recurrence	at 9 months	4 [10.0%]	3 [7.5%]	0.155	0.694
Grade Same grade Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence Same site of primary tumor 2 [66.7%] 1 [33.3%] 0.558 0.455 Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same grade 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 0 [0%] 0 [0%] 0 [0%]	Site	Another site recurrence	1 [25.0%]	0 [0%]	0.750	0.387
Progression 0 [0%] 0 [0%] 0 [0%] Stage Same stage 4 [100%] 3 [100%] 0.00 1.00 Progression 0 [0%] 3 [100%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 1 [33.3%] 0.558 0.455 Same site of primary tumor 1 [33.3%] 2 [66.7%] 3 [100%] 0.999 0.318 Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 0 [0%] 2.502 0.114		Same site of primary tumor	3 [100%]	3 [100%]		
Stage Same stage Progression 4 [100%] 0 [0%] 3 [100%] 0 [0%] 0.00 1.00 Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence Same site of primary tumor 2 [66.7%] 1 [33.3%] 0.558 0.455 Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114	Grade	Same grade	4 [100%]	3 [100%]	0.00	1.00
Progression 0 [0%] 0 [0%] 0 [0%] 0 [0%] Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 1 [33.3%] 0.558 0.455 Same site of primary tumor 1 [33.3%] 2 [66.7%] 1 [00%] 0.00 1.00 Grade Same grade 2 [66.7%] 3 [100%] 0.999 0.318 Progression 1 [33.3%] 0 [0%] 0 [0%] 0 [0%] 0 [0%] Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114		Progression	0 [0%]	0 [0%]		
Recurrence at 12 months 3 [7.5%] 3 [7.5%] 0.00 1.00 Site Another site recurrence 2 [66.7%] 1 [33.3%] 0.558 0.455 Same site of primary tumor 1 [33.3%] 2 [66.7%] 3 [100%] 0.999 0.318 Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114	Stage	e	4 [100%]	3 [100%]	0.00	1.00
Site Another site recurrence Same site of primary tumor 2 [66.7%] 1 [33.3%] 1 [33.3%] 2 [66.7%] 0.558 0.455 Grade Same grade Progression 2 [66.7%] 1 [33.3%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114		Progression	0 [0%]	0 [0%]		
Same site of primary tumor 1 [33.3%] 2 [66.7%] Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 0 [0%] 2.502 0.114	Recurrence at 12 months		3 [7.5%]	3 [7.5%]	0.00	1.00
Grade Same grade Progression 2 [66.7%] 3 [100%] 0.999 0.318 Stage Same stage 1 [33.3%] 0 [0%] 2.502 0.114	Site	Another site recurrence	2 [66.7%]	1 [33.3%]	0.558	0.455
Progression 1 [33.3%] 0 [0%] Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114		Same site of primary tumor				
Stage Same stage 1 [33.3%] 3 [100%] 2.502 0.114	Grade				0.999	0.318
		Progression	1 [33.3%]			
Progression 2 [66.7%] 0 [0%]	Stage	e			2.502	0.114
	-	Progression	2 [66.7%]	0 [0%]		

x²: Chi-square test; p-value>0.05 NS

DISCUSSION

Bladder tumor is the commonest malignancy in urinary system; approximately, 75–80% of patients are NMIBCs at the time of diagnosis ^[7]. The mainstay method for the

management of NMIBC is TURBT. Initial resection aims to resect all tumors involving the underlying muscle of the bladder ^[8].

TURBT was done previously using conventional monopolar electro cautery loop and non-saline irrigation fluid, which carries the risk of absorption of hypotonic fluid and electrolyte disturbance ^[9]. Also, the obturator reflex may produce when the resectoscopes electrical current stimulates the obturator nerve directly, especially if the tumor is placed on the bladder's lateral wall ^[10].

Many researches have been demonstrated favorable outcomes for B-[TURBT], including less incidence of bladder perforation due to minimal depth, improved homeostasis, and a shorter hospital stay ^[11]. The essential benefit of bipolar electro cautery is that it causes minimal charring and blackening of tissue. Also, it provides maximal anatomical visibility, allowing for controlled resection while avoiding damage to surrounding organs. Other benefit of bipolar power is evident by managed patients with high-risk tumors, as those with pacemakers or pregnancy ^[12].

TUR syndrome after M-TURBT is rarely recorded, with incidence of about 2% ^[13]. In our study there is no TUR syndrome occurred in both groups; this seems to be due to the less open venous channels, small size tumor, and short time of resection, despite scientific evidence of a slight decline in sodium levels in monopolar TURBT and bipolar TURBT, no one of the patients experienced manifestation of diluted hyponatremia. Furthermore, no significant statistical reduction was detected in the level of sodium. These results agree with Venkatramani et al. that found no significant difference in clinical TUR syndrome between monopolar and bipolar tumor excision ^[14]. Also, Botal et al. reported that B-[TURBT] has no significant advantage than M-[TURBT] in decrease the occurrence of TUR syndrome ^[15]. However, Avallone et al. demonstrated less incidence of TUR syndrome in B-[TURBT], due to the use of saline for flushing mainly ^[16].

Bladder damage in TURBT is uncommon, but it carries a substantial risk of extravesical tumor seeding ^[17]. In this study, bladder perforation was not detected in any case in both groups; these data agree with **Mashni** *et al.* that recorded no development of bladder perforation, with no significant different between M-polar and B-polar TURBT ^[18], and **Liem** *et al.* reported no statistical difference between M-polar and B-polar TURBT regarding bladder perforation ^[19]. However, our results disagree with Sugihara *et al.* that found the rate of vesical damage considerably higher in M polar-TURBT compared to Bpolar TURBT [0.3 % vs. 0.6 %], indicating the superiority of the B polar-TURBT ^[20]. Also, Mansour *et al.* found that monopolar resection had a 13.2 % perforation rate, which was considerably greater than the 2.4 % for bipolar resection [P= 0.02] ^[21], and **Yanjie** *et al.*, in nine RCTs included 1193 patients , reported that there was significantly reduced in bladder perforation in B-[TURBT] than M-[TURBT] [P=0.002] ^[22].

In our study, obturator reflex was elevated in the M polar-TURBT group, affecting ten [25%] cases vs. 2 [5%] patients in the B polargroup, which was statistically TURBT significant [P=0.013], this might be due to that the most of patients in our study had lateral wall urinary bladder mass. These data agree with **Mansour** et al. who observed a substantial decrease in nerve stimulation incidence from 26.5 percent with M polar-TURBT to 4.8 percent with B polar-TURBT [P=0.01]^[21], and **Manish** *et al.* who found that the incidence of obturator jerk was less in bipolar group but without significant difference $[p=0.073]^{[23]}$. However, our results do not agree with Ozer et al. who reported that the obturator reflux was statistically higher in the B polar-TURBT group; with the obturator reflex observed in 15 [34%] patients vs. four [8%] [P= 0.001] ^[24]. Also, Venkatramani *et al.* found that the incidence of obturator jerk was higher in the B-TURBT [60 vs. 49.2 %, P= $0.271^{[14]}$.

Multiple investigations have found that regardless of the type of energy employed, the resection time was the same in both M-polar and B-polar resectoscopes ^[24]. In our study, there was a minimal shorter operative time in B-polar than M-polar without a significant difference between the two groups. These data agree with **Venkatramani** *et al.* found no significant variation in resection time in their study ^[14]. Also, **Liem** *et al.* believes that there is no great disparity in operative time between the two groups, possibly because B-TURBT employs a smaller loop, which takes longer than M-TURBT ^[19]. However, previous research has shown that B-TURBT has a much shorter operative time than M-TURBT. This is due to the ability of quick hemostasis to create a clean surgical region. Furthermore, adherence of residual debris to the resectoscope is less common in B-TURBT, and if it does occur, it is swiftly removed without the need for manual removal as slowly as in M-TURBT ^[8], and Teoh *et al.* did a systematic review on 1360 patients which found that a shorter resection time I B-[TURBT] than M- [TURBT] ^[25].

In our study, we observed mild hematuria more in monopolar than bipolar and blood transfusion to three cases in monopolar and to one case in bipolar but without statistically significant difference [p= 0.308], our results agree with Gupta et al, that recorded less postoperative hematuria in bipolar which was statistically non-significant, and not clinically significant as there was no need for coagulation or blood transfusion in either group ^[26], and Fagerstrom et al. detected when compared to the monopolar method, bipolar resection has a more efficient property of cutting while concurrently managing bleeding ^[27]. Also, Venkatramani et al. did not find blood loss to be significantly different between monopolar and bipolar groups ^[14].

In our study, there was a mild drop in hemoglobin and hematocrit level in M-polar than B-polar without significant difference between the two groups; these data agree with Geavlete et al. which reported a lower hemoglobin decline in B-TURBT, but the need for blood transfusion was not statistically different between the two groups ^[28], and Venkatramani et al. who reported no significant difference between M-TURBT and B-TURBT for the drop in Hb level and hematocrit value ^[14]. In contrast, Yang *et al.* reported a significant drop in Hb level with M-TURBT vs. B-TURBT, [p=0.038], which was not reflected in the transfusion rate ^[29]. Also, Hashad et al. reported the postoperative drop in Hb concentration in the B-TURBT group was substantially smaller [mean 0.55 [g/dL] compared to the M -TURBT group [mean 1.24 g/dL; P < 0.001]. There was also a significant difference [in favor of B-TURBT] in the mean

postoperative hematocrit decline between the groups ^[30]. Also, Mao et al, showed that M-[TURBT] had a greater decrease in postoperative Hg level than G-[TURBT] [P=0.02] ^[31].

There is universal agreement that the use of bipolar resection reduced the catheterization time and hospital stay due to better control of intraoperative bleeding ^[20]. In our study, the catheterization and hospitalization time were significantly lower in the B-TURBT group vs. the M-TURBT group [p = 0.003 & 0.008]respectively. These data agree with Hashad et al. that recorded a statistical difference in the post-operative catheterization and mean hospital stay in favor of B-TURBT^[30], and **Del** Rosso et al. also reported a significant reduction in the catheterization and hospital time with B-TURBT, vs. the monopolar ^[8]. Conversely, Ozer et al. recorded that the mean catheterization and hospital stay was reduced in the monopolar vs. in the bipolar, but this was not statistically significant ^[24]. Also, Liem et discovered no statistically significant al. difference between the two groups as regarded hospitalization and catheterization time ^[19].

In our study, there was no difference between the two groups regarding the rate of recurrence of bladder tumors over the 1-year follow-up. Our results agree with Xie *et al.* that observed no difference between the M-TURBT and B- TURBT groups ^[32]. Also, in other study by Del Rosso *et al.*, there was no different in the recurrence-free survival rate when comparing the two procedures ^[8].

The main strength of the present study is the prospective nature and long-term follow up of the patients. In addition, the variation of bladder cancer presentation makes a valuable comparison between various subcategories.

Conclusion: B polar-TURBT is considered the most safe and effective alternative technique than M polar-TURBT for the treatment of primary NMIBT.

Financial support: Nil.

Conflicts of interest: No conflict of interest was detected.

REFERENCES

- 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71[1]:7-33. DOI: 10.3322/caac.21654.
- 2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, *et al.* Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 Feb;63[2]:234-41. DOI: 10.1016/j.eururo.2012.07.033.
- 3. Dunsmuir WD, McFarlane JP, Tan A, Dowling C, Downie J, Kourambas J, *et al.* Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y followup. Prostate Cancer Prostatic Dis. 2003;6[2]:182-6. DOI: 10.1038/sj.pcan. 4500631.
- 4. Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009 Nov;56[5]:798-809. DOI: 10.1016/j.eururo.2009.06.037.
- Michielsen DP, Debacker T, De Boe V, Van Lersberghe C, Kaufman L, Braeckman JG, Amy JJ, Keuppens FI. Bipolar transurethral resection in saline--an alternative surgical treatment for bladder outlet obstruction? J Urol. 2007 Nov;178[5]:2035-9; discussion 2039. DOI: 10.1016/j.juro.2007.07.038.
- 6. Issa MM. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol. 2008; 22[8]:1587-95. DOI: 10.1089/end.2008.0192.
- Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, *et al.* Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-387. DOI: 10.1016/j.ejca.2018.07.005.
- Del Rosso A, Pace G, Masciovecchio S, Saldutto P, Galatioto GP, Vicentini C. Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: a single center randomized controlled trial. Int J Urol. 2013 Apr;20[4]:399-403. DOI: 10.1111/j.1442-2042.2012.03174.x.
- Chopin DK, Gattegno B. Superficial bladder tumors. Eur Urol. 2002 Dec;42[6]:533-41. DOI: 10.1016/s0302-2838[02]00466-9.
- 10. So PC. Two case reports of obturator nerve block for transurethral resection of bladder

tumour. Hong Kong Med J. 2004 Feb;10[1]:57-9. PMID: 14967858.

- Wang DS, Bird VG, Leonard VY, Plumb SJ, Konety B, Williams RD, Winfield HN. Use of bipolar energy for transurethral resection of bladder tumors: pathologic considerations. J Endourol. 2004 Aug;18[6]:578-82. DOI: 10. 1089/end.2004.18.578.
- 12. Lee D, Sharp VJ, Konety BR. Use of bipolar power source for transurethral resection of bladder tumor in patient with implanted pacemaker. Urology. 2005 Jul;66[1]:194. DOI: 10.1016/j.urology.2005.01.006.
- 13. Dorotta I, Basali A, Ritchey M, O'Hara JF Jr, Sprung J. Transurethral resection syndrome after bladder perforation. Anesth Analg. 2003 Nov;97[5]:1536-1538. DOI: 10.1213/01.ANE. 0000085299.24288.8C.
- Venkatramani V, Panda A, Manojkumar R, Kekre NS. Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol. 2014 Jun;191[6]:1703-7. DOI: 10.1016/j.juro.2013.12.004.
- 15. Bolat D, Gunlusoy B, Aydogdu O, Aydin ME, Dincel C. Comparing the short - term outcomes and complications of monopolar and bipolar transurethral resection of bladder tumors in patients with coronary artery disese: a prospective, randomized, controlled study. Int Braz J Urol. 2018 Jul-Aug;44[4]:717-725. DOI: 10.1590/S1677-5538.IBJU.2017.0309.
- 16. Avallone MA, Sack BS, El-Arabi A, Charles DK, Herre WR, Radtke AC, Davis CM, See WA. Ten-Year Review of Perioperative Complications After Transurethral Resection of Bladder Tumors: Analysis of Monopolar and Plasmakinetic Bipolar Cases. J Endourol. 2017 Aug;31[8]:767-773. DOI: 10.1089/end. 2017.0056.
- Traxer O, Pasqui F, Gattegno B, Pearle MS. Technique and complications of transurethral surgery for bladder tumours. BJU Int. 2004 Sep;94[4]:492-6. DOI: 10.1111/j.1464-410X. 2004.04990.x.
- 18. Mashni J, Godoy G, Haarer C, Dalbagni G, Reuter VE, Al-Ahmadie H, Bochner BH. Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. Int Urol Nephrol. 2014 Sep;46[9]:1699-705. DOI: 10.1007/s11255-014-0719-9.

- Liem EIML, McCormack M, Chan ESY, Matsui Y, Geavlete P, Choi YD, *et al.* Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. Urol Oncol. 2018; 36[7]:338. e1-338.e11. DOI: 10.1016/j.urolonc.2018.03. 015.
- 20. Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Nishimatsu H, Nakagawa T, *et al.* Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: a population based comparison. J Urol. 2014 Nov;192[5]:1355-9. DOI: 10.1016/j.juro.2014.05.100.
- 21. Mansour AM, Shokeir AA, Tharwat M, Ali-El-Dein B, Osman Y. Pd17-10 monopolar versus bipolar transurethral resection of non-muscle invasive bladder cancer: a single center randomized controlled trial. J Urol. 2015 Apr;193[4S]:e384-5.
- Ma Y, Sun L, Lin X, Zhang W, Wang D. Efficacy and safety of bipolar versus monopolar transurethral resection of bladder tumors: A meta-analysis of randomized controlled trials. J Cancer Res Ther. 2020;16[7]:1588-1595. DOI: 10.4103/jcrt.JCRT_539_20.
- 23. Pradhan MM, Poudyal S, Chapagain S, Luitel BR, Chalise PR, Sharma UK, Gyawali PR. Safety and efficacy of bipolar vs monopolar transurethral resection of bladder tumor-A randomized controlled trial. Nepal Med College J. 2020 Nov 2;22[3]:123-8.
- 24. Ozer K, Horsanali MO, Gorgel SN, Ozbek E. Bladder injury secondary to obturator reflex is more common with plasmakinetic transurethral resection than monopolar transurethral resection of bladder cancer. Cent European J Urol. 2015;68[3]:284-8. DOI: 10.5173/ceju.2015.565.
- 25. Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, *et al.* An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol. 2020 Oct;78[4]:546-569. DOI: 10.1016/j.eururo.2020.04.059.

- 26. Gupta NP, Saini AK, Dogra PN, Seth A, Kumar R. Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. BJU Int. 2011 Aug;108[4]:553-6. DOI: 10.1111/j.1464-410X.2010.09903.x.
- Fagerström T, Nyman CR, Hahn RG. Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique: a single-centre randomized trial of 202 patients. BJU Int. 2010 Jun;105[11]:1560-4. DOI: 10.1111/j.1464-410X.2009.09052.x.
- Geavlete B, Mulflescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Bipolar vaporization-Advantages of a new technique in bladder cancer endoscopic treatment. Roman J Urol. 2011 Dec 1;10[4]:37-40.
- 29. Yang SJ, Song PH, Kim HT. Comparison of deep biopsy tissue damage from transurethral resection of bladder tumors between bipolar and monopolar devices. Korean J Urol. 2011 Jun;52[6]:379-83. DOI: 10.4111/kju.2011.52. 6.379.
- Hashad MM, Abdeldaeim HM, Moussa A, Assem A, Youssif TMA. Bipolar vs monopolar resection of bladder tumours of >3 cm in patients maintained on low-dose aspirin: A randomised clinical trial. Arab J Urol. 2017 May 31;15[3]:223-227. DOI: 10.1016/j.aju. 2017.04.001.
- 31. Mao X, Zhou Z, Cui Y, Zhang Y, Yang M. Outcomes and Complications of Bipolar vs. Monopolar Energy for Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Surg. 2021 Jun 2;8:583806. DOI: 10.3389/fsurg.2021.583806.
- 32. Xie K, Cao D, Wei Q, Ren Z, Li J, Li Y, Fu M. Bipolar versus monopolar transurethral resection of non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials. World J Urol. 2021;39[4]:1177-1186. DOI: 10.1007/s00345-020-03271-3.



International Journal

https://ijma.journals.ekb.eg/ Print ISSN: 2636-4174

Online ISSN: 2682-3780 Of Medical Arts